Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.

This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.

This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This study found that Wet-type Age-Related Macular Degeneration patients had higher oxidative stress and HMGB-1 levels compared to healthy controls, suggesting a link to increased tissue inflammation and necrosis.

In this review, researchers explored the multifaceted role of NF-κB signaling in various biological processes and diseases, including its interactions with other pathways, and discussed possible therapeutic approaches targeting this pathway for treating conditions like cancer, autoimmune disorders, and COVID-19.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

This case report highlights a rare instance of erosive pustular dermatosis of the scalp in a patient on afatinib, underlining the importance of early recognition and management of this adverse effect.

This review discusses the variety of skin changes and diseases that can occur during pregnancy, categorizing them into physiological changes, non-specific alterations, and pregnancy-specific dermatoses, and reports no clinical results.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review discusses the mechanisms and pathways of FGFR signalling and its roles in development, disorders, and therapeutic targeting, but reports no new clinical results.

This study suggests that the GPX-PDE1 and GPX-PDE2 genes in white lupin enhance root hair development and contribute to Pi limitation acclimation by facilitating glycerophosphodiester degradation.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This review discusses the potential of plant polyphenols to overcome multidrug resistance in various solid cancers and reports no new experimental results; further research is suggested.

This review addresses the role of skin-resident adult stem/progenitor cells in skin homeostasis, disease, and cancer development, and reports no new research results.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

This source explores long COVID syndrome and identifies risk factors like older age, female gender, and comorbidities such as diabetes. It mentions potential diagnostic biomarkers, highlights ongoing clinical trials, and emphasizes the importance of vaccines and rehabilitation in managing long COVID.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This report documents two cases of eruptive nevi occurring in the skin folds of children with Langerhans cell histiocytosis.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review provides a comprehensive overview of multidisciplinary dermo-aesthetic interventions for breast cancer patients, aiming to establish safe protocols involving various specialists to improve quality of life, although consultation with an oncologist before treatment is advised.

This review provides an in-depth analysis of the structure and function of c-kit activation, and its role in both normal physiological and pathological conditions, with no new research findings reported.